Summary
Abbott Laboratories reported solid financial results for the third quarter and first nine months of 2024, showcasing robust top-line growth driven by its Medical Devices and Established Pharmaceutical Products segments. Despite a notable decline in COVID-19 testing sales, the company achieved an overall 4.9% increase in net sales in Q3 and 3.7% for the nine-month period, with organic growth (excluding foreign exchange) at 7.4% and 6.7%, respectively. The Medical Devices segment, in particular, demonstrated strong double-digit growth in key areas like Diabetes Care, Electrophysiology, and Structural Heart, highlighting successful product launches and strategic partnerships. Profitability also saw improvement, with gross profit margins increasing year-over-year due to higher pricing and efficiency initiatives, partially offsetting foreign exchange headwinds. While research and development expenses saw a modest increase, selling, general, and administrative costs were managed effectively. The company also continues to prioritize shareholder returns through dividend payments and share repurchases, demonstrating confidence in its financial stability and future outlook. However, investors should remain aware of ongoing legal proceedings, particularly the significant jury verdict in an infant formula lawsuit, although Abbott plans to appeal and does not currently believe a material loss is probable. Additionally, ongoing tax examinations by the IRS present a potential area of future scrutiny.
Financial Highlights
51 data points| Revenue | $10.63B |
| Cost of Revenue | $4.70B |
| Gross Profit | $5.94B |
| R&D Expenses | $713.00M |
| SG&A Expenses | $2.90B |
| Operating Expenses | $8.78B |
| Operating Income | $1.86B |
| Net Income | $1.65B |
| EPS (Basic) | $0.94 |
| EPS (Diluted) | $0.94 |
| Shares Outstanding (Basic) | 1.74B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Total net sales increased by 4.9% to $10.635 billion in Q3 2024 and by 3.7% to $30.976 billion for the first nine months of 2024, with organic growth (excluding foreign exchange) of 7.4% and 6.7% respectively.
- 2Medical Devices segment demonstrated strong performance with an 11.7% increase in Q3 and 12.0% increase for the nine months (excluding foreign exchange), driven by significant growth in Diabetes Care, Electrophysiology, and Structural Heart products.
- 3Gross profit margin improved to 51.4% in Q3 2024 and 51.0% for the nine months, up from 49.7% and 50.1% in the prior year periods, respectively, reflecting pricing benefits and efficiency initiatives.
- 4Diluted Earnings Per Common Share (EPS) rose to $0.94 in Q3 2024 from $0.82 in Q3 2023, and to $2.38 for the nine months from $2.35 in the prior year.
- 5The company repurchased approximately 7 million shares for $750 million in Q3 2024 and announced a new $7 billion share repurchase program, underscoring commitment to shareholder returns.
- 6COVID-19 testing-related sales continued to decline, impacting the Diagnostic Products segment, with sales down 24.0% (excluding FX) for Rapid Diagnostics in the first nine months.
- 7Abbott faces significant legal proceedings, including a $495 million jury verdict in an infant formula NEC lawsuit, which the company plans to appeal. Reserves have not been recorded as a material loss is not deemed probable.